Abstract | AIMS: To evaluate the effect of the chronic use of apraclonidine 0.5% on the intraocular pressure (IOP) of patients with glaucoma; also, to study the side effect profile of this drug when used chronically. METHODS: All patients who had uncontrolled IOP, who were either already on glaucoma medications, or who were intolerant of other glaucoma medications were enrolled. A total of 185 patients were started on apraclonidine 0.5% two to three times a day in one eye. RESULTS: Follow up extended to 35 weeks. The mean difference in IOP between treated and control eyes was 2.1 (SD 5.0) mm Hg. A similar IOP lowering effect was obtained comparing IOP difference from baseline in the treated eye only. CONCLUSION: By the end of the follow up period, 46% of patients were still on the medication. The drug was stopped in 23% of patients because of side effects and in 31% of patients because of failure to lower IOP significantly.
|
Authors | S V Araujo, J B Bond, R P Wilson, M R Moster, C M Schmidt Jr, G L Spaeth |
Journal | The British journal of ophthalmology
(Br J Ophthalmol)
Vol. 79
Issue 12
Pg. 1098-101
(Dec 1995)
ISSN: 0007-1161 [Print] England |
PMID | 8562543
(Publication Type: Journal Article)
|
Chemical References |
- Adrenergic alpha-Antagonists
- apraclonidine
- Clonidine
|
Topics |
- Adolescent
- Adrenergic alpha-Antagonists
(adverse effects, therapeutic use)
- Adult
- Aged
- Aged, 80 and over
- Clonidine
(adverse effects, analogs & derivatives, therapeutic use)
- Female
- Follow-Up Studies
- Glaucoma
(drug therapy, physiopathology)
- Humans
- Intraocular Pressure
(drug effects)
- Male
- Middle Aged
|